<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717298</url>
  </required_header>
  <id_info>
    <org_study_id>OOS-CANCER-6</org_study_id>
    <nct_id>NCT03717298</nct_id>
  </id_info>
  <brief_title>Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma</brief_title>
  <official_title>Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesized that with the administration of the nutritional supplement
      Ocoxin-Viusid® is expected to improve the quality of life and enhance tolerance to
      chemotherapy in at least 70% of patients diagnosed with advanced pancreatic adenocarcinoma,
      treated at the &quot;Hermanos Ameijeiras&quot; Surgical Clinical Hospital. Phase II clinical trial,
      open, multicenter, nonrandomized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the effect of Ocoxin-Viusid® on the quality of life of patients with advanced
      pancreatic adenocarcinoma.

      To evaluate the effect of Ocoxin-Viusid® on the quality of life of patients. To evaluate the
      influence of Ocoxin-Viusid® on tolerance to onco-specific therapy.

      Identify the changes that occur in the nutritional status of patients receiving the
      supplement.

      To evaluate the toxicity of Ocoxin-Viusid® in combination with chemotherapy in patients with
      advanced pancreatic adenocarcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life: EORTC QLQ-C30</measure>
    <time_frame>12 months</time_frame>
    <description>Life quality measurement through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (ORTC QLQ-C30): an integrated system for assessing the healthrelated quality of life (QoL) of cancer patients participating in international clinical trials. It's composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nutritional Status of the patient during Chemotherapy</measure>
    <time_frame>12 months</time_frame>
    <description>Variations in the patient's nutritional status will be considered, measured by body mass Index (a measure of body fat based on height and weight that applies to adult men and women)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events-AE during Chemotherapy Test</measure>
    <time_frame>12 months</time_frame>
    <description>A test with the following questions:
Occurrence of an AE in the subject [Yes, No]; Description of the AE [Name of the event]; Duration of the AE [Difference between the start and end date of the event]; Intensity of the AE [According to CTCAE version 4 it will classify in Light, Moderate, Severe, Life-threatening consequences, Death related to AE]; Seriousness of the AE [serious or not serious], Attitude with respect to the treatment under study [No changes, dose modification, temporary or definitive interruption of the study treatment], Result of the AE [recovered, improved, persisted or sequelae], Causal relationship [According to WHO algorithm it will classify in very probable, probable, possible, improbable, unrelated, not evaluable]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology test</measure>
    <time_frame>12 months</time_frame>
    <description>Levels of Hemoglobin, Platelets, Hemogram with differential in blood extractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry test</measure>
    <time_frame>12 months</time_frame>
    <description>Measure levels of GPT, GOT, Creatinine, Glycemia, Bilirrubin, Alkaline Phosphatase, LDH in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with the treatment with chemotherapy (CT) and Immunotherapy (IT) test</measure>
    <time_frame>12 months</time_frame>
    <description>Test with the next parameters: if the administration of chemotherapy (CT) and Immunotherapy (IT) treatments will be considered at planned time, number of the cycle administered out of date, days elapsed since the previous cycle and, cause that caused the administration of the CT/IT outside the planned date. In the case of the dose, the medication in which it was modified will be taken into account, as well as the modified dose.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Advanced Cancer</condition>
  <condition>Digestive System Neoplasms</condition>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Endocrine Gland Neoplasms</condition>
  <condition>Digestive System Diseases</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Pancreatic Diseases</condition>
  <arm_group>
    <arm_group_label>Ocoxin-Viusid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It will be used at a rate of 60 ml daily (1 vial every 12 hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ocoxin-Viusid®</intervention_name>
    <description>An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.
The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.
The treatment will be administered continuously from the inclusion of the patient in the study, up to one year.</description>
    <arm_group_label>Ocoxin-Viusid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of any sex, resident in Cuba, with an age greater than or equal to 18 years.

          -  Patients that meet the diagnostic criteria.

          -  Patients with general health according to Karnofsky ≥70 %.

          -  Life expectancy greater than or equal to 3 months.

          -  Patients eligible to receive chemotherapy.

          -  Patients who have signed the informed consent.

          -  Patients who have laboratory values in parameters that do not contraindicate the
             administration of chemotherapy:

          -  Hemoglobin ≥ 90 g / l.

          -  Total Leukocyte Count ≥ 3.0 x 109 / L.

          -  Absolute Neutrophil Count ≥1.5 x 109 / L.

          -  Platelet count ≥100 x 109 / L.

          -  Total bilirubin values ≤ 1.5 times the upper limit of the normal range established in
             the institution.

          -  TGO and TGP values ≤2.5 times the upper limit of the normal interval established in
             the institution.

          -  Creatinine values within the normal limits of the institution.

        Exclusion Criteria:

          -  Pregnant or lactating patients.

          -  Patients with known hypersensitivity to any of the active ingredients of the
             chemotherapy used

          -  Patients who are receiving another product under investigation.

          -  Patients with decompensated intercurrent diseases, including: hypertension, diabetes
             mellitus, ischemic heart disease, active infections, symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia, liver damage or any other
             special condition that at the discretion of the doctor puts their health at risk and
             his life during the study or his participation in the trial.

          -  Patients with brain metastases.

          -  Patients with mental disorders that may limit adherence to the requirements of the
             clinical trial and may hinder the collection of information, treatment or follow-up.

        It is planned to include a total of 30 patients in the study, taking into account 10% of
        losses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ivis Mendoza Hernández, MSc</last_name>
    <phone>7 204 8742</phone>
    <email>ivis@cencec.sld.cu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaima Muñoz Morejón, Dr.</last_name>
    <phone>7 204 8742</phone>
    <email>yaima@cencec.sld.cu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>&quot;Hermanos Ameijeiras&quot; Surgical Clinical Hospital</name>
      <address>
        <city>La Habana</city>
        <zip>10300</zip>
        <country>Cuba</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayté Lima Pérez, Dr.</last_name>
      <email>mayte.lima@infomed.sld.cu</email>
    </contact>
    <contact_backup>
      <last_name>Juan L. Soriano García, Dr.</last_name>
      <email>soriano@infomed.sld.cu</email>
    </contact_backup>
    <investigator>
      <last_name>Mayte Lima Pérez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge L. Soriano García, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vilma Fleites Calvo, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Ortiz, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María E. Suardiaz, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yolanda Hernández García, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amarilis Grau Cascudo, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivelisse Fleites, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Domínguez, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robin García Diéguez, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Gutiérrez, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <reference>
    <citation>Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403-13.</citation>
    <PMID>9196156</PMID>
  </reference>
  <reference>
    <citation>Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.</citation>
    <PMID>21561347</PMID>
  </reference>
  <reference>
    <citation>Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.</citation>
    <PMID>24131140</PMID>
  </reference>
  <reference>
    <citation>Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Inokuchi S, Makuuchi H. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med. 2003 Mar;11(3):305-9.</citation>
    <PMID>12579331</PMID>
  </reference>
  <reference>
    <citation>Burris H 3rd, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist. 2008 Mar;13(3):289-98. doi: 10.1634/theoncologist.2007-0134. Review.</citation>
    <PMID>18378539</PMID>
  </reference>
  <reference>
    <citation>Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K, Mochizuki H. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 2004 Jul;29(1):e1-8.</citation>
    <PMID>15211117</PMID>
  </reference>
  <reference>
    <citation>Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5141-4.</citation>
    <PMID>3014534</PMID>
  </reference>
  <reference>
    <citation>Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006 Jun;448(6):788-96. Epub 2006 Apr 6.</citation>
    <PMID>16598499</PMID>
  </reference>
  <reference>
    <citation>Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007 Apr 15;109(8):1561-9.</citation>
    <PMID>17354229</PMID>
  </reference>
  <reference>
    <citation>Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, Bazan V, Fulfaro F. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology. 2009;77 Suppl 1:57-68. doi: 10.1159/000258497. Epub 2010 Feb 2. Review.</citation>
    <PMID>20130433</PMID>
  </reference>
  <reference>
    <citation>da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer. 2010 Dec 15;116(24):5599-607. doi: 10.1002/cncr.25393. Epub 2010 Sep 7.</citation>
    <PMID>20824720</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nutritional supplement</keyword>
  <keyword>Advanced Pancreatic adenocarcinoma</keyword>
  <keyword>Ocoxin-Viusid</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Antioxidant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

